Lipocine Inc (LPCN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -3,672 | -9,628 | -7,257 | -4,071 | -1,865 |
| Depreciation Amortization | -82 | -132 | -81 | -61 | -43 |
| Accounts payable and accrued liabilities | 591 | 700 | 590 | 171 | 89 |
| Other Working Capital | 1,431 | -244 | 308 | 140 | -133 |
| Other Operating Activity | -526 | -458 | -400 | -35 | -18 |
| Operating Cash Flow | $-2,257 | $-9,761 | $-6,841 | $-3,856 | $-1,969 |
| Cash Flows From Investing Activities | |||||
| Purchase Of Investment | -15,204 | -14,709 | -10,281 | -5,082 | -5,082 |
| Sale Of Investment | 5,300 | 20,600 | 14,600 | 8,700 | 4,200 |
| Investing Cash Flow | $-9,904 | $5,891 | $4,319 | $3,618 | $-882 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 11,971 | 2,870 | 217 | 76 | N/A |
| Financing Cash Flow | $11,971 | $2,870 | $217 | $76 | $N/A |
| Beginning Cash Position | 5,206 | 6,206 | 6,206 | 6,206 | 6,206 |
| End Cash Position | 5,016 | 5,206 | 3,901 | 6,044 | 3,355 |
| Net Cash Flow | $-190 | $-1,000 | $-2,305 | $-162 | $-2,851 |
| Free Cash Flow | |||||
| Operating Cash Flow | -2,257 | -9,761 | -6,841 | -3,856 | -1,969 |
| Free Cash Flow | -2,257 | -9,761 | -6,841 | -3,856 | -1,969 |